| Next 10 |
Ad
VSTM News and Press Verastem Inc.
News | Verastem Inc. (NASDAQ:VSTM)
-
2024-12-11 03:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2024-11-29 13:24:46 ET DENVER, Colo., Nov 29, 2024 ( 247marketnews.com ) – MoBot’s recent alerts involved; Unusual Machines (NYSE: UMAC ) and Archer Aviation (NYSE: ACHR ), and Bitdeer Technologies (NASDAQ: BTDR ) set new 52-week highs; wh...
-
2024-11-27 13:28:34 ET Summary Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company’s strong cash position and strategic focus on RAS-driven cancers of...
-
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 rd at 11:1...
-
2024-11-07 02:34:37 ET More on Verastem Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem Read the fu...
-
Completed rolling NDA submission for avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer in October 2024 Company seeking accelerated approval and priority review of its NDA submission for patients with KRAS mutant low-grade serous ovarian cance...
-
2024-11-01 09:13:05 ET More on Verastem Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem Read the fu...
-
Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Company seeking accelerated approval and priority review of its NDA submission in patients with KRAS mutant low-grade serous ovarian cancer; FDA filing decision expected before the end of 2024 with ...
-
Verastem, Inc. (NASDAQ: VSTM) is one of today's top gainers. The company's shares have moved 20.57% on the day to $3.57. Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development inclu...
-
A look at the top 10 most actives in the United States Lucid Group Inc. (LCID) fell 15.1% to $2.785 on volume of 61,420,308 shares NVIDIA Corporation (NVDA) rose 2.7% to $139.43 on volume of 51,188,821 shares Tevogen Bio Holdings Inc. (TVGN) rose 62.1% to $1.6862 on volume of 45,809,605 sha...
Stock Information
Get VSTM Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2024-12-11 03:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2024-11-29 13:24:46 ET DENVER, Colo., Nov 29, 2024 ( 247marketnews.com ) – MoBot’s recent alerts involved; Unusual Machines (NYSE: UMAC ) and Archer Aviation (NYSE: ACHR ), and Bitdeer Technologies (NASDAQ: BTDR ) set new 52-week highs; wh...
-
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 rd at 11:1...